Reboxetine
From Ganfyd
rINN: Reboxetine
Other Names
Edronax®
Pharmacological Information
Web information on Reboxetine
Mechanism of Action
a selective noradrenaline uptake inhibitor
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Medpedia on Reboxetine (Less technical, good quality control)
Wikipedia on Reboxetine (Less technical, ? quality control)
Contents |
Indication
Depressive illness
Dose
4mg twice daily: increase if necessary after 2-4 weeks to 10 -12mg daily in divided doses.
Clinical Issues
A meta-analysis of all randomised controlled trials done until 2009 has shown that the drug is an ineffective antidepressant relative to selective serotonin reuptake inhibitors [1]. There is publication bias. It transpires that a number of the trials were completed after the drug was first licensed in parts of the EU in 1997 to comply with FDA requirements.
References
- ↑ Eyding D, Lelgemann M, Grouven U, Härter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ (Clinical research ed.). 2010; 341:c4737.(Epub)
